VEGFA and plasma cell myeloma: Thalidomide and the newer IMiDs have also been shown to significantly decrease the expression of angiogenic factors VEGF and Interleukin-6 (IL-6) in multiple myeloma; thereby reducing angiogenesis and hence contributing to clinical activity in multiple myeloma[26].